We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Novel AIA Adversarial Procedures for Challenging Validity of Pharmaceutical Patents

04 February 2015

Westlaw Journal Intellectual Property, Volume 21, Issue 21
Since September 2012, patent challengers have been able to take advantage of three new proceedings to attack patent validity at the U.S. Patent and Trademark Office under the America Invents Act: inter partes review, post grant review and a transitional program for covered business method patents. Each proceeding is conducted in an adversarial "trial" format before the Patent Trial and Appeal Board. These proceedings offer several advantages over traditional federal court litigation for those challenging patents — including pharmaceutical patents.


Loading data